Avanza Fonder AB Has $5.09 Million Stock Position in Cencora, Inc. (NYSE:COR)

Avanza Fonder AB lessened its position in Cencora, Inc. (NYSE:COR - Free Report) by 17.4% during the first quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 18,224 shares of the company's stock after selling 3,852 shares during the quarter. Avanza Fonder AB's holdings in Cencora were worth $5,094,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also bought and sold shares of COR. Stratos Wealth Partners LTD. acquired a new stake in Cencora in the 4th quarter valued at approximately $205,000. Apollon Wealth Management LLC raised its position in Cencora by 14.1% in the 4th quarter. Apollon Wealth Management LLC now owns 5,353 shares of the company's stock valued at $1,203,000 after buying an additional 660 shares during the last quarter. WCM Investment Management LLC raised its position in Cencora by 99.1% in the 4th quarter. WCM Investment Management LLC now owns 2,116 shares of the company's stock valued at $476,000 after buying an additional 1,053 shares during the last quarter. Savant Capital LLC raised its position in Cencora by 4.1% in the 4th quarter. Savant Capital LLC now owns 7,312 shares of the company's stock valued at $1,643,000 after buying an additional 291 shares during the last quarter. Finally, Latitude Advisors LLC acquired a new stake in Cencora in the 4th quarter valued at approximately $559,000. Institutional investors and hedge funds own 97.52% of the company's stock.

Wall Street Analyst Weigh In

Several research firms have weighed in on COR. Citigroup boosted their price target on Cencora from $330.00 to $355.00 and gave the stock a "buy" rating in a research report on Thursday, May 8th. Bank of America boosted their price target on Cencora from $270.00 to $285.00 and gave the stock a "neutral" rating in a research report on Friday, April 11th. UBS Group boosted their price target on Cencora from $298.00 to $335.00 and gave the stock a "buy" rating in a research report on Tuesday, April 29th. Morgan Stanley set a $288.00 price target on Cencora in a research report on Tuesday, April 15th. Finally, Wall Street Zen raised Cencora from a "hold" rating to a "buy" rating in a research report on Wednesday, March 12th. One investment analyst has rated the stock with a hold rating and ten have issued a buy rating to the stock. According to data from MarketBeat, Cencora has an average rating of "Moderate Buy" and an average target price of $306.91.

Insider Activity at Cencora

In related news, EVP Elizabeth S. Campbell sold 4,127 shares of the business's stock in a transaction on Monday, March 24th. The stock was sold at an average price of $268.28, for a total value of $1,107,191.56. Following the completion of the sale, the executive vice president now directly owns 14,665 shares in the company, valued at $3,934,326.20. The trade was a 21.96% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Chairman Steven H. Collis sold 14,578 shares of the stock in a transaction on Tuesday, March 25th. The stock was sold at an average price of $269.51, for a total value of $3,928,916.78. Following the sale, the chairman now directly owns 317,913 shares in the company, valued at approximately $85,680,732.63. This trade represents a 4.38% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 38,253 shares of company stock worth $10,582,297 in the last ninety days. 10.80% of the stock is owned by company insiders.

Cencora Stock Performance

Shares of COR stock traded up $0.08 during trading on Friday, reaching $295.12. 966,888 shares of the company's stock were exchanged, compared to its average volume of 1,528,880. The company has a quick ratio of 0.54, a current ratio of 0.92 and a debt-to-equity ratio of 16.40. The stock has a market capitalization of $57.20 billion, a PE ratio of 41.98, a PEG ratio of 1.31 and a beta of 0.58. Cencora, Inc. has a twelve month low of $218.65 and a twelve month high of $309.35. The firm's fifty day moving average price is $287.24 and its 200-day moving average price is $261.74.

Cencora (NYSE:COR - Get Free Report) last released its quarterly earnings results on Wednesday, May 7th. The company reported $4.42 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.07 by $0.35. The business had revenue of $75.50 billion during the quarter, compared to the consensus estimate of $75.41 billion. Cencora had a return on equity of 328.62% and a net margin of 0.46%. The firm's quarterly revenue was up 10.3% on a year-over-year basis. During the same period in the previous year, the company posted $3.80 EPS. As a group, sell-side analysts anticipate that Cencora, Inc. will post 15.37 EPS for the current year.

Cencora Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Monday, June 2nd. Investors of record on Friday, May 16th were paid a $0.55 dividend. The ex-dividend date of this dividend was Friday, May 16th. This represents a $2.20 annualized dividend and a yield of 0.75%. Cencora's dividend payout ratio (DPR) is presently 25.52%.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.